Journal of Trace Elements in Medicine and Biology 28 (2014) 427–430

Contents lists available at ScienceDirect

Journal of Trace Elements in Medicine and Biology

journal homepage: www.elsevier.de/jtemb

Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment

Stephen G. Kaler*,[1]

Section on Translational Neuroscience; Molecular Medicine Program, NICHD, Porter Neuroscience Research Center II, Building 35, Room 2D-971, 35A Convent Drive, MSC 3754, National Institutes of Health, Bethesda, MD 20892-3754, United States

ARTICLE INFO

Keywords:
Menkes disease
ATP7A
Copper
Neurodevelopment
Brain growth

ABSTRACT

Menkes disease is an X-linked recessive disorder of brain copper metabolism caused by mutations in an essential mammalian copper transport gene, *ATP7A*. Untreated affected individuals suffer failure to thrive and neurodevelopmental delays that usually commence at 6–8 weeks of age. Death by age three years is typical. While provision of working copies of *ATP7A* to the brain by viral vectors is a promising strategy under development, the only treatment currently available is subcutaneous copper injections. These can normalize circulating blood levels and may replete brain copper depending on the molecular context, e.g., the severity of ATP7A mutation and potential presence of mosaicism. In this paper, we summarize somatic growth and neurodevelopmental outcomes for 60 subjects enrolled in a recently concluded phase I/II clinical trial of copper histidine for Menkes disease (ClinicalTrials.gov Identifier: NCT00001262). Primary outcomes indicate highly statistically significant improvements in gross motor, fine motor/adaptive, personal-social, and language neurodevelopment in the cohort of subjects who received early treatment prior to onset of symptoms ($n = 35$). Correlating with these findings, quantitative parameters of somatic growth indicated statistically significant greater growth in head circumference for the initially asymptomatic group, whereas weight and height/length at age three years (or at time of death) did not differ significantly. Mortality at age 3 was higher (50%) in subjects older and symptomatic when treatment commenced compared to the asymptomatic group (28.6%). We conclude that early copper histidine for Menkes disease is safe and efficacious, with treatment outcomes influenced by the timing of intervention, and ATP7A mutation.

Published by Elsevier GmbH.

Introduction

Successful management of orphan pediatric neurometabolic diseases is often complicated by difficulty in the early diagnosis and institution of effective therapy before irrevocable brain damage. Without reliable newborn screening to detect asymptomatic affected infants, early diagnosis relies upon a high index of suspicion based on positive family history, or astute clinical judgment by neonatal care providers.

Menkes disease, an X-linked recessive disorder of brain copper metabolism, is one such condition for which early diagnosis is crucial for any prospect of meaningful long-term outcome. First described in 1962 [1], the illness is caused by mutations in a highly evolutionarily conserved copper-transporting P-type ATPase, ATP7A [2–5]. Treatment for Menkes disease with copper replacement was first suggested by Danks et al. [6] and has been applied by others [7–12]. Clinical outcomes in response to various copper regimens have been mixed, however, and the need for alternative or supplemental remedies has been cited [13–15].

In a Phase I/II clinical trial (ClinicalTrials.gov Identifier: NCT00001262), we evaluated the effects of a specific copper treatment regimen on neurodevelopment and somatic growth in 60 patients with a proven diagnosis of Menkes disease.

Materials and methods

Patients

Fifty-seven individuals identified as having classic Menkes disease based on evidence of disturbed copper transport, including

* Tel.: +1 301 451 6034; fax: +1 301 480 8657.
E-mail address: kalers@mail.nih.gov

[1] The work reported herein was carried out at the NIH Clinical Center and funded by the Intramural Research Programs of NICHD and NINDS, and grants from the International Copper Association, and Children's National Medical Center, Washington, DC.

http://dx.doi.org/10.1016/j.jtemb.2014.08.008
0946-672X/Published by Elsevier GmbH.

Table 1
Neurodevelopmental outcomes and growth at 36 mos of age (or at death) after copper histidine treatment in Menkes disease.

Subject	Gross motor (mos)	Fine motor (mos)	Personal social (mos)	Language (mos)	Weight (centile)	Length (centile)	OFC (centile)	*ATP7A* mutation	Death ≤3 yrs
Group I									
I-01[26]	3	4	6	6	0	0	0	IVS8 AS dup5	
I-02[26]	2	2	2	2	0	0	0	IVS8 AS dup5	
I-03[18,28]	1	1	1	1	10	0	25	R201X	D
I-04[12]	2	2	2	3	0	0	0	Q724H	
I-05	1	1	1	2	0	0	10	4195del4	D
I-06	1	1	1	1	10	5	10	2926/7 GG > TT	D
I-07	1	1	1	1	15	10	0	2926/7 GG > TT	D
I-08	1	2	1	1	0	40	0	IVS6 DS, +1g > a	D
I-09	2	2	1	1	15	15	25	ND	D
I-10	2	2	1	2	0	0	0	Del exon 1	
I-11	10	1	1	2	5	50	15	2233 delT	
I-12	6	8	15	12	50	0	0	A629P	
I-13	2	3	10	10	0	0	5	G728D	
I-14	5	2	5	4	0	0	0	ND	D
I-15	1	4	5	5	3	60	10	Q724X	
I-16	2	2	1	1	0	10	25	IVS21 AS -1, G > A	D
I-17	2	3	4	5	50	50	40	IVS12 DS +1, g > a	D
I-18[27]	2	2	4	2	50	75	50	G727R	D
I-19	1	4	5	3	5	5	5	R201X	
I-20	4	1	2	1	10	5	0	S487X	
I-21	2	1	1	2	25	15	25	Q843X	D
I-22	1	4	4	4	0	0	0	ND	
Mean	2.455	2.409	3.364	3.227	11.273	15.455	11.136		11 of 22
SD	2.154	1.652	3.499	2.943	17.097	23.192	14.551		50%
Group II									
II-01[12]	12	15	15	10	5	0	10	Q724H	
II-02[17,30]	5	4	6	7	0	0	5	W1187X	D
II-03[12]	2	3	2	2	0	0	40	Q724H	D
II-04[26]	36	36	36	36	0	0	60	IVS8 AS dup5	
II-05[30]	5	4	4	4	0	0	0	IVS7 AS -1G > C	
II-06[28]	36	36	36	36	25	15	50	R201X	
II-07[30]	13	15	24	20	50	10	75	Q197X	
II-08[19,30]	4	4	4	5	0	0	0	K1037N	D
II-09[25]	3	3	5	5	0	0	50	Del exon 1	D
II-10[14]	4	6	6	8	5	10	75	2757/8 delAG	D
II-11[14]	12	16	24	16	0	0	0	G666R	
II-12[14,30]	7	11	13	8	50	5	50	Del exon 7–19	
II-13[14]	4	21	15	12	0	20	25	Del exon 1	
II-14	3	3	5	4	5	5	50	IVS7 AS -1, G > C	
II-15[14]	36	36	36	33	40	25	40	IVS9 DS +6 t > g	
II-16[14]	24	30	28	27	80	15	50	3936/7 delT	
II-17[14]	2	2	2	2	0	5	0	3061 del T	
II-18[14]	34	36	36	32	20	10	40	G666R	
II-19[21]	3	2	4	3	0	5	0	IVS11 SA -1, G > A	
II-20[20]	30	30	32	24	0	75	25	ND	
II-21[14]	12	16	15	14	0	0	0	del 4246–4260	
II-22[14]	1	1	1	1	10	25	0	Q1383X	D
II-23[14]	2	4	3	6	0	10	0	3061 del T	
II-24[21,27]	30	30	38	30	0	0	60	G727R	
II-25[14,30]	2	4	3	4	25	10	0	Del ex 20–23	
II-26[29,30]	1	1	2	1	5	5	50	Del ex 13–14	D
II-27[30]	11	15	17	24	5	5	50	IVS15 DS -1, G > A	D
II-28	24	28	34	30	50	5	90	Del exon 1	
II-29[22]	10	14	19	17	0	0	0	L625X	D
II-30[21]	15	18	24	20	3	5	25	Del ex 2–14	
II-31	24	28	24	32	5	5	50	1020 dup5	
II-32[27]	32	34	38	34	10	10	50	G727R	
II-33	2	3	3	2	5	5	25	ND	D
II-34	24	28	32	20	25	5	60	Del 2–23	
II-35	16	30	32	24	0	0	60	Del exon 1	
Mean	13.743	16.200	17.657	15.800	12.086	8.286	33.286		10 of 35
SD	12.200	12.762	13.482	12.034	19.589	13.501	27.060		28.6%
P values: Group I v II	<0.0001	<0.0001	<0.0001	<0.0001	0.8735	0.1453	0.0009		
Group III									
III-01[23]	27	32	35	31	15	75	50	S833G	
III-02	10	15	12	20	0	10	0	ND	
III-03[23]	10	6	6	12	0	0	5	IVS21 DS +3, a > t	
Mean	15.667	17.667	17.667	21.000	5.000	28.333	18.333		0 of 3
SD	9.815	13.204	15.308	9.539	8.660	40.723	27.538		0%

Group I: Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms. **Group II**: Classic Menkes disease: Copper histidine treatment beginning within 1 month of age and prior to onset of symptoms. **Group III**: Milder variants of Menkes disease: Copper histidine treatment beginning late after onset of (milder) symptoms. D = deceased; ND = not determined. Superscripts refer to previous reports (see References) in which the respective subjects were mentioned. For growth, centile = 0 indicates below or at the lower limit of normal.